Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the full year 2024. For the year, the company expects Product Revenues to be between $580.0 million to $595.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.76 USD | -0.59% | -4.31% | +3.18% |
Jun. 13 | Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity | MT |
Jun. 07 | Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.18% | 1.04B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024